as on February 28, 2026 at 7:59 am IST
Day's Low
Day's High
5.19%
Downside
-0.03%
Upside
52 Week's Low
52 Week's High
44.17%
Downside
27.32%
Upside
Check Viking Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$3.8B
EPS (TTM)
-4.1148
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
-0.03
EBITDA
-
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-47.34%
Compare market cap, revenue, PE, and other key metrics of Viking Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $3.8B | 402.08% | NA | 0.00% | |
| BUY | $122.0B | 133.75% | 31.34 | 32.94% | |
| BUY | $43.9B | 124.79% | 142.78 | 8.45% | |
| NA | $35.7B | NA | 619.94 | 1.38% | |
| BUY | $81.5B | 73.48% | 18.59 | 31.41% |
The Viking Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Viking Therapeutics, Inc. investment value today
Current value as on today
₹1,21,692
Returns
₹21,692
(+21.69%)
Returns from Viking Therapeutics, Inc. Stock
₹17,388 (+17.39%)
Dollar Returns*
₹4,304 (+4.3%)
Based on 17 analysts
94.12%
Buy
5.88%
Hold
0.00%
Sell
Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for Viking Therapeutics, Inc.. Average target price of $92.72
Get share price movements and forecasts by analysts on Viking Therapeutics, Inc..
What analysts predicted
63.45%UPSIDE
Target Price
$92.72
Current Price
$33.89
Analyzed by
17 Analysts
Target
$92.72
Viking Therapeutics, Inc. target price $92.72, a slight upside of 63.45% compared to current price of $33.89. According to 17 analysts rating.
Investment in Viking Therapeutics, Inc. Shares on INDmoney has dropped by -42.52% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Viking Therapeutics, Inc. Stock has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 12 February
Thu, 06:14 PM
-Viking Therapeutics jumps 16% after announcing Phase 3 development plans for its oral obesity drug and reporting a wider loss.
Thu, 06:33 PM
-Viking reports a fourth-quarter loss of $1.38 per share, wider than expected, while advancing its oral obesity drug into late-stage development.
Thu, 11:17 PM
-Viking Therapeutics shares rise 8% following the announcement of advancing its oral obesity drug into Phase 3 development.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 3 Years
![]()
In the last 3 years, VKTX has outperformed top 5 stocks with highest market-cap in its industry
Price Rise
![]()
In the last 7 days, VKTX stock has moved up by 9.1%
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 34.9% return, outperforming this stock by 17.7%
| Organisation | Viking Therapeutics, Inc. |
| Headquarters | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Industry | Health Technology |
| CEO | Dr. Brian Lian Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Brian Lian Ph.D. | President, CEO & Director |
Mr. Gregory S. Zante CPA | Chief Financial Officer |
Ms. Marianne Mancini | Chief Operating Officer |
Mr. Michael Morneau | Vice President of Finance & Administration |
Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales |
Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer |
Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations |
Viking Therapeutics, Inc. share price today is $33.89 as on at the close of the market. Viking Therapeutics, Inc. share today touched a day high of $33.88 and a low of $32.13.
Viking Therapeutics, Inc. share touched a 52 week high of $43.15 on and a 52 week low of $18.92 on . Viking Therapeutics, Inc. stock price today i.e. is closed at $33.89,which is 21.46% down from its 52 week high and 79.12% up from its 52 week low.
Viking Therapeutics, Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Viking Therapeutics, Inc. (VKTX) shares with as little as ₹91.026 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹910.26 in Viking Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Viking Therapeutics, Inc. share’s latest price of $33.89 as on February 28, 2026 at 2:29 am IST, you will get 0.2951 shares of Viking Therapeutics, Inc.. Learn more about
fractional shares .
Viking Therapeutics, Inc. stock has given 402.08% share price returns and 23.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?